An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

PURPOSE: To determine ombrabulin’s maximum tolerated dose and dose recommended for Japanese patients with advanced solid tumors and to assess its antitumor activity and overall safety and pharmacokinetic profiles. METHODS: This was a multi-center, open-label, sequential-cohort, dose-escalation phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Murakami, H., Kurata, T., Onozawa, Y., Watanabe, J., Ono, A., Takahashi, T., Yamamoto, N., Fujisaka, Y., Kiyota, H., Hayashi, H., Tanaka, K., Nakagawa, K., Kuroda, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931931/
https://www.ncbi.nlm.nih.gov/pubmed/24477603
http://dx.doi.org/10.1007/s00280-014-2388-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931931/
https://www.ncbi.nlm.nih.gov/pubmed/24477603
http://dx.doi.org/10.1007/s00280-014-2388-x

Ejemplares similares